Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05252949Not ApplicableCompleted

OEA for Targeting Lipid Metabolism in GWI

Role: lead

NCT05736146Recruiting

Validating Gulf War Illness Blood Biomarkers

Role: lead

NCT05243290Not ApplicableRecruiting

Nicotinamide Riboside Clinical Trial for GWI

Role: lead

NCT06883227Recruiting

Investigating Health Impacts of Exposure to Harmful Algal Blooms

Role: lead

NCT03082638Completed

Identification of Gulf War Illness (GWI) Biomarkers

Role: lead

NCT03974399Not ApplicableCompleted

BDNF Levels After Bacopa

Role: lead

NCT01669876Phase 2Terminated

Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease

Role: collaborator

NCT01607619Not ApplicableCompleted

Effect of Anatabine on Elevated Blood Levels of C-reactive Protein

Role: lead

All 8 trials loaded